Key facts
- This page summarizes James Darecca's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Aug 2021, 21:33.
James Darecca - 10 Aug 2021 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- TXMD
- Reported as of
- 10 Aug 2021
- Net transaction value
- -$81,203
- SEC form
- 4
- Accepted by SEC
- 12 Aug 2021, 21:33:45 UTC
- Prior SEC filing
- 02 Jul 2021
- Next SEC filing
- 14 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ James C. D'Arecca
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James Darecca filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 12 Aug 2021.
Change
- Previous filing in this sequence was filed on 02 Jul 2021.
- Current net transaction value: -$81,203.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TXMD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +217,167
- Change %
- Price
- Shares after
- 217,167
- Date
- 10 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
TXMD
transaction
Common Stock
Sale
- Transaction value
- $81,203
- Shares
- -93,337
- Change %
- -43%
- Price
- $0.8700*
- Shares after
- 123,830
- Date
- 12 Aug 2021
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TXMD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -217,167
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 434,333
- Date
- 10 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 217,167
- Exercise price
- $0.000000
- Footnotes
- F1, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.
Footnote F2
The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Footnote F4
Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
Footnote F5
The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023.